他扎罗汀乳膏短时接触疗法治疗寻常痤疮的临床研究

目的 评价0.1%他扎罗汀乳膏短时接触疗法治疗寻常痤疮时能否有效减轻局部不良反应,以及对临床疗效和症状反复的影响.方法 多中心、随机对照方法,将纳入观察的187例寻常痤疮病例分为短时接触疗法8周组,短时接触疗法12周组和常规治疗组.按Doshi痤疮综合分级系统(GAGS)计分评价,观察在治疗开始前(基线期)、完成时以及完成后的第2、4、8周内症状变化情况,评估局部不良反应和疗效,以及对病情反复的影响.结果 短时接触疗法8周组、12周组和常规治疗组局部不良反应率分别为11.48%、12.90%和38.33%,三组比较,差异有统计学意义(X2=13.31,P<0.01).短时接触疗法12周组总有效率(80.65%)较8周组(63.93%)高(X2=3.84,P<0.05).三组总有效率比较,差异无统计学意义(X2=1.98,P>0.05).短时接触疗法12周组能明显降低病情反复,三组间2,4、8周各随访段病情反复率比较,差异均有统计学意义(X2=3.29,3.78和5.85,P<0.05或P<0.01).结论 0.1%他扎罗汀乳膏短时接触疗法治疗寻常痤疮能有效减轻局部不良反应,且不降低疗效;而延长短时接触疗法疗程能减少症状反复,提高疗效.     

0．1％他扎罗汀乳膏短时接触疗法治疗面部痤疮疗效观察

目的：观察0．1％他扎罗汀乳膏短时接触疗法治疗轻、中度面部寻常痤疮的临床疗效和安全性。方法：采用随机、单盲及平行对照的临床研究方法分组观察比较0．1％他扎罗汀乳膏短时接触疗法与常规疗法治疗面部痤疮的疗效和安全性。结果：治疗组24例患者外用0．1％他扎罗汀乳膏短时接触疗法后2周、4周和8周的有效率分别为25．0％、41．7％及70．8％，对照组24例患者外用0．1％他扎罗汀乳膏常规疗法疗后2周、4周和8周的有效率分别为20．8％、45．8％及75．0％，两组疗效差异无统计学意义；治疗组与对照组的不良反应发生率分别为4．2％及29．6％，治疗组不良反应发生率显著低于对照组（P〈0．05）。结论：0．1％他扎罗汀乳膏短时接触疗法治疗轻、中度面部寻常痤疮疗效好，不良反应少，有很好的耐受性。     

他扎罗汀乳膏短时接触疗法治疗寻常痤疮的临床研究

目的 评价0.1%他扎罗汀乳膏短时接触疗法治疗寻常痤疮时能否有效减轻局部不良反应,以及对临床疗效和症状反复的影响。方法 多中心、随机对照方法,将纳入观察的187例寻常痤疮病例分为短时接触疗法8周组,短时接触疗法12周组和常规治疗组,按Doshi痤疮综合分级系统（GAGS）计分评价,观察在治疗开始前（基线期）、完成时以及完成后的第2、4、8周内症状变化情况,评估局部不良反应和疗效,以及对病情反复的影响。结果 短时接触疗法8周组、12周组和常规治疗组局部不良反应率分别为11.48%、12.90%和38.33%,三组比较,差异有统计学意义（χ2 = 13.31,P < 0.01）。短时接触疗法12周组总有效率（80.65%）较8周组（63.93%）高（χ2 = 3.84,P < 0.05）。三组总有效率比较,差异无统计学意义（χ2 = 1.98,P > 0.05）。短时接触疗法12周组能明显降低病情反复,三组间2、4、8周各随访段病情反复率比较,差异均有统计学意义（χ2 = 3.29,3.78和5.85,P < 0.05 或P < 0.01）。结论 0.1%他扎罗汀乳膏短时接触疗法治疗寻常痤疮能有效减轻局部不良反应,且不降低疗效;而延长短时接触疗法疗程能减少症状反复,提高疗效。     

0.1%他扎罗汀乳膏短时接触隔日维持治疗对寻常痤疮复发的影响

目的:评价0.1%他扎罗汀乳膏短时接触隔日维持治疗对寻常痤疮复发的影响及其安全性.方法:采用多中心、随机、双盲、安慰剂对照方法,对纳入观察的126例经治疗后症状缓解达到Pillsbury分级法属I级以下的寻常痤疮患者.采用0.1%他扎罗汀乳膏(或安慰剂)短时接触隔日维持治疗,按Doshi的痤疮综合分级系统(the global ache grading system,GAGS)计分评价,观察维持疗程第4、8、12周症状变化情况,评估其对症状复发的影响.结果:0.1%他扎罗汀乳膏维持治疗组较安慰剂组的复发率明显降低,在随访的第8和12周复发率差异有统计学意义(χ~2=5.255和8.147,P<0.05);两组无论是轻、中、重度,还是局部不良反应发生率均相近,发生率极低.总的局部不良反应发生率(3.33%/1.69%)比较差异无统计学意义(χ~2=0.325、P>0.05).结论:0.1%他扎罗汀乳膏短时接触隔日维持治疗能减少寻常痤疮复发,且局部不良反应少,具有一定的临床应用价值.     

0.05%他扎罗汀治疗寻常痤疮疗效观察

目的 观察他扎罗汀凝胶治疗寻常痤疮的临床疗效.方法 治疗组70例,外用0.05%他扎罗汀乳膏,每晚1次;对照组45例,外用0.025%维A酸乳膏,每晚1次,均连用8周观察疗效.结果 治疗组有效率68.7%:对照组为49.5%.两组比较差异有统计学意义(P<0.05).结论 0.05%他扎罗汀乳膏治疗寻常痤疮有确切疗效.     

阿维A胶囊联合他扎罗汀乳膏治疗中重度痤疮52例疗效观察

目的：观察阿维A胶囊联合他扎罗汀乳膏治疗中、重度痤疮的疗效。方法：治疗组口服阿维A胶囊10mg，每天2次，同时皮损外用0.1％他扎罗汀膏，每晚1次；对照组皮损仅外用0.1％他扎罗汀乳膏，每晚1次，两组疗程均8周。结果：治疗组总有效率为90．38％，对照组总有效率为60％，两组比较差异有统计学意义（X^2=11．13，P〈0．01）。结论：阿维A胶囊联合他扎罗汀乳膏治疗中重度痤疮疗效满意。     

0.1%他扎罗汀乳膏联合罗红霉素治疗痤疮临床观察

目的观察0.1%他扎罗汀乳膏联合罗红霉素治疗痤疮的疗效。方法以0.1%他扎罗汀乳膏外用联合罗红霉素口服作为治疗组,单纯罗红霉素口服作为对照组,观察疗效。结果治疗组有效率优于对照组(P<0.01)。治疗组未见明显不良反应。结论0.1%他扎罗汀乳膏联合罗红霉素治疗痤疮效果好,值得临床推广。     

0.1%他扎罗汀凝胶接触治疗寻常痤疮疗效观察

目的：观察0．1％他扎罗汀凝胶短期接触治疗轻、中度面部寻常痤疮的临床疗效和安全性。方法：采用随机、平行对照的临床研究方法，入选病例外涂试验药物，每天2次，疗程12周。结果：治疗组疗后2、4、8、12周的有效率分别为24％、40％、60％、68％；对照组分别为19．2％(P=0．631)、23．1％(P=0．175)、30．8％(P=0．034)、30．8％(P=0．008)。结论：0．1％他扎罗汀凝胶短期接触治疗轻中度面部寻常痤疮疗效好，不良反应轻，有较好的耐受性。     

异维A酸红霉素凝胶治疗轻、中度寻常性痤疮临床观察

目的观察异维A酸红霉素凝胶治疗轻、中度寻常性痤疮的疗效和安全性。方法采用单盲随机阳性药物对照的临床试验。治疗组采用异维A酸红霉素凝胶,每晚外用1次;对照组采用他扎罗汀乳膏,每晚外用1次,连续应用56天。结果治疗后,两组皮损数目均减少。治疗组和对照组有效率分别为80.56%和65.71%,差异有统计学意义(P<0.05);两组不良反应发生率分别为13.89%和21.34%,差异无统计学意义(P>0.05)。结论异维A酸红霉素凝胶治疗轻、中度寻常性痤疮安全有效,值得临床推广应用。     

夫西地酸联合他扎罗汀治疗中度寻常痤疮的疗效观察

目的 探讨夫西地酸联合他扎罗汀外用治疗痤疮的临床疗效和安全性.方法 采用随机数字法,将79例中度痤疮患者随机分为2组:治疗组39例,给予夫西地酸乳膏外用,每天2次,他扎罗汀乳膏点涂,每晚1次,4周为1个疗程,共用2个疗程;对照组40例,给予甲硝唑凝胶外用,每天2次,他扎罗汀乳膏点涂,每晚1次,疗程同治疗组.治疗结束时,通过计算症状积分下降指数(SSRI)、痊愈率及有效率评价临床疗效.全程记录不良反应.结果 结果:治疗结束时,治疗组36例、对照组33例全程完成了试验.治疗组36例中痊愈19例(52.78％),SSRI为0.87±0.12,对照组痊愈12例(36.37％),SSRI为0.61±0.09,治疗组显著高于(均P＜0.01),治疗组有效13例(36.11％),也较对照组(10例,30.30％)为高,但差异无统计学意义(P＞0.05).部分患者发生不良反应但可耐受,未发现系统不良反应.结论 夫西地酸与他扎罗汀外用治疗痤疮疗效确切、不良反应轻微.     

Spotlight on Adapalene in Acne Vulgaris

Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris. In clinical trials, 0.1% adapalene gel has proved to be effective in this indication and was as effective as 0.025% tretinoin gel, 0.1% tretinoin microsphere gel, 0.05% tretinoin cream and 0.1% tazarotene gel once every two days; however, the drug was less effective than once-daily 0.1% tazarotene gel. It can be used alone in mild acne or in combination with antimicrobials in inflammatory acne and has proved efficacious as maintenance treatment. Adapalene has a rapid onset of action and a particularly favorable tolerability profile compared with other retinoids. These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris.     

Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study

Previous investigations have reported the efficacy of tazarotene 0.1% cream for the treatment of dyschromia associated with photoaging and for acne vulgaris. The present investigation assessed tazarotene 0.1% cream for the treatment of postinflammatory hyperpigmentation (PIH) in a double-blind, randomized, vehicle-controlled study of 74 patients from darker racial ethnic groups who had acne. Once-daily application of tazarotene cream was shown to be effective against PIH, achieving significantly greater reductions compared with vehicle in overall disease severity and in the intensity and area of hyperpigmentation within 18 weeks (P< or =.05). Mean levels of erythema, burning, and peeling were no more than trace in both groups throughout the study, and mean levels of dryness were no more than mild in both groups. In our study, tazarotene cream was effective and well tolerated in the treatment of PIH in patients with darker skin.     

Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.

Retinoids reverse the abnormal pattern of keratinization seen in acne vulgaris. Tazarotene is the first of a novel family of topical receptor-selective acetylenic retinoids. This study evaluates the safety and efficacy of topical tazarotene 0.1% and 0.05% gels, in comparison to vehicle gel, applied once daily for 12 weeks, in the treatment of mild-to-moderate facial acne vulgaris. A total of 446 patients with facial acne vulgaris were enrolled, and 375 patients, ranging in age from 14 to 44 years, were evaluable in this multicenter, double-blind, randomized study. In comparison to vehicle gel, treatment with tazarotene 0.1% gel resulted in significantly greater reductions in noninflammatory and total lesion counts at all follow-up visits, and inflammatory lesion counts at Week 12. Tazarotene 0.05% gel resulted in significantly greater reductions in noninflammatory and total lesion counts than vehicle gel at Weeks 8 and 12. At Week 12, treatment success rates were 68% and 51% for tazarotene 0.1% and 0.05%, respectively (40% for vehicle gel). Tazarotene gel was an effective, safe, and generally well-tolerated therapy for the treatment of acne vulgaris.     

Optimizing treatment with topical tazarotene

Tazarotene is a receptor-selective retinoid, which is efficacious in the treatment of patients with psoriasis, acne vulgaris, and photoaging. It normalizes keratinocyte differentiation, reverses keratinocyte hyperproliferation, and has anti-inflammatory effects. Clinical studies have shown that tazarotene 0.1% gel has greater comedolytic activity than tretinoin (Retin-A 0.025% gel, Retin-A Micro 0.1%) and adapalene (Differin) 0.1% gel. Although it is efficacious as monotherapy, tazarotene is more commonly used as part of combination therapy with a topical antibacterial in patients with acne vulgaris, and with a mid- or high-potency topical corticosteroid or with phototherapy in patients with psoriasis. Combination therapy enhances efficacy and tolerability. Tazarotene 0.1% gel, used in combination with mometasone furoate 0.1% cream, was shown in psoriasis clinical trials to be more efficacious than calcipotriene (calcipotriol) ointment used twice daily, or mometasone furoate 0.1% cream used twice daily. Use of tazarotene in conjunction with broad band UVB, narrow band UVB or bath psoralens + UVA (PUVA) results in greater efficacy than with phototherapy alone. Tazarotene should not be administered during pregnancy or in women who are not practicing adequate contraception. Adverse events consist primarily of irritation, peeling, erythema, dryness, burning, and itching. They are most common during the first 1-2 weeks of therapy and can be minimized with use of the cream formulation, alternate day application, short contact therapy, mild cleansers, and combination therapy.     

Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris

Topical retinoids are the cornerstone of therapy for acne vulgaris. Nevertheless, the adjunctive use of other anti-acne agents can help enhance the efficacy of topical retinoids still further. Given that tazarotene 0.1 percent gel has previously shown significantly greater efficacy than tretinoin 0.025 percent gel, it is likely that tazarotene plus clindamycin offers superior efficacy to tretinoin plus clindamycin, which has recently become available as a combination product. A total of 150 patients with facial acne vulgaris were randomly assigned to receive either tazarotene 0.1 percent cream plus clindamycin 1 percent gel, or tretinoin 0.025 percent gel plus clindamycin 1 percent gel. Each medication was applied once daily in the evening (clindamycin followed by the retinoid 5-10 minutes later) for up to 12 weeks. At week 12, the reduction from baseline in lesion counts was greater with tazarotene/clindamycin than tretinoin/clindamycin for both the non-inflammatory lesion count (71% vs. 52%, p< or =.01) and the inflammatory lesion count (77% vs. 67%, P=.053). Tazarotene/clindamycin also resulted in a significantly higher incidence of patients achieving > or = 50 percent global improvement (incidence of 88% vs. 75% at week 12; p< or =.05). Both regimens were similarly well tolerated. In the treatment of facial acne vulgaris, tazarotene plus clindamycin offers significantly greater efficacy than tretinoin plus clindamycin and has comparable tolerability.     

Randomised,controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris

BACKGROUND: Previous clinical trials have shown that adapalene gel produces less irritation than tretinoin gels and tretinoin 0.025% cream. Short term results have shown that adapalene is less irritating than tretinoin gels and creams. This study is the first to compare the 0.1% formulation of adapalene gel with the 0.05% strength of tretinoin cream in a formal clinical trial. OBJECTIVE: To investigate the efficacy and tolerability of adapalene gel 0.1% compared with tretinoin cream 0.05% in patients with mild-to-moderate acne vulgaris. METHODS: Ten-week, multicentre, randomised, investigator-masked, active-controlled, parallel group study in 409 patients with acne vulgaris. RESULTS: Adapalene gel 0.1% demonstrated equivalent efficacy in reduction of acne lesion counts and global improvement of acne severity over 10 weeks' treatment and was significantly better tolerated than tretinoin cream 0.05% in terms of erythema, dryness, desquamation and stinging/burning. CONCLUSION: Adapalene gel 0.1% showed equivalent efficacy and was significantly better tolerated than tretinoin cream 0.05% in patients with mild-to-moderate acne vulgaris.